CD-NP is a novel chimeric natriuretic peptide in clinical development for the treatment of acute heart failure. CD-NP was designed to preserve the favorable effects of current therapies while preventing or attenuating the hypotensive response, and enhancing renal function, the company said.
Results from two completed Phase I studies and the ongoing open-label Phase IIa study support advancing the CD-NP development program into a Phase IIb clinical study.
Current development plans include initiating a 30 patient placebo-controlled clinical study of acute heart failure patients with renal impairment. This study is designed to assess safety and efficacy of early administration of CD-NP in this patient population and may provide additional evidence to support the hypothesis that CD-NP enhances renal function.
Nile also announced that it will suspend the further development of 2NTX-99 and return license rights for the compound to Cesare Casagrande. 2NTX-99 is a small molecule anti-platelet, anti-atherothrombotic agent with nitric oxide donating properties.
Peter Strumph, CEO of Nile, said: We are disappointed that we are unable to continue to pursue the development of 2NTX-99. We have decided to terminate this program in order to focus our resources on our core natriuretic peptide program, which is showing great promise as a potential treatment for cardiovascular and renal disease.